Your browser is no longer supported. Please, upgrade your browser.
HOOK HOOKIPA Pharma Inc. daily Stock Chart
HOOKIPA Pharma Inc.
Index- P/E- EPS (ttm)-4.91 Insider Own- Shs Outstand25.74M Perf Week24.92%
Market Cap212.87M Forward P/E- EPS next Y-2.50 Insider Trans- Shs Float18.39M Perf Month3.12%
Income- PEG- EPS next Q-0.65 Inst Own48.90% Short Float0.87% Perf Quarter19.68%
Sales13.27M P/S16.05 EPS this Y-27.60% Inst Trans0.21% Short Ratio3.72 Perf Half Y-40.93%
Book/sh7.07 P/B1.17 EPS next Y12.90% ROA- Target Price19.80 Perf Year-
Cash/sh5.24 P/C1.58 EPS next 5Y-4.80% ROE- 52W Range6.06 - 14.76 Perf YTD-40.93%
Dividend- P/FCF- EPS past 5Y- ROI37.90% 52W High-43.97% Beta-
Dividend %- Quick Ratio8.70 Sales past 5Y- Gross Margin- 52W Low36.47% ATR0.43
Employees60 Current Ratio8.70 Sales Q/Q524.20% Oper. Margin- RSI (14)63.32 Volatility7.71% 5.39%
OptionableNo Debt/Eq0.04 EPS Q/Q- Profit Margin- Rel Volume0.35 Prev Close8.38
ShortableYes LT Debt/Eq0.04 EarningsNov 11 AMC Payout- Avg Volume43.18K Price8.27
Recom1.40 SMA2012.96% SMA509.84% SMA200-4.06% Volume15,209 Change-1.31%
Sep-27-19Initiated H.C. Wainwright Buy $15
May-13-19Initiated RBC Capital Mkts Outperform $23
May-13-19Initiated BofA/Merrill Buy $17
Sep-25-19 08:30AM  HOOKIPA Announces Key Hires to its Executive Team GlobeNewswire
Sep-19-19 08:55AM  HOOKIPA to Present Data Demonstrating the Potential of its TheraT® Technology at the Upcoming CICON Conference in Paris GlobeNewswire
Aug-29-19 08:30AM  HOOKIPA Pharma to Present at Upcoming Investor Conferences in September GlobeNewswire +9.44%
Aug-12-19 04:01PM  HOOKIPA Pharma Reports Second Quarter 2019 Financial Results and Clinical Progress Highlights GlobeNewswire
Jul-19-19 01:37PM  What Kind Of Shareholders Own HOOKIPA Pharma Inc. (NASDAQ:HOOK)? Simply Wall St. +5.31%
Jul-17-19 10:06AM  Biotech Stock Roundup: Galapagos & Hookipa Surge, AMGN Shelves Alzheimer's Study Zacks +10.77%
Jul-12-19 07:58AM  Dow Jones Futures: Illumina, Profitable Marijuana Stock Tumble; Amgen-Novartis Alzheimer's Drug Fails Investor's Business Daily +22.90%
07:24AM  The Daily Biotech Pulse: Hookipa Leaps, Illumina Dims On Q2 Warning, Novartis-Amgen Halt Alzheimer's Study Benzinga
Jul-11-19 04:37PM  Hookipa Pharma jumps 40% after FDA approval of clinical tests MarketWatch
04:01PM  HOOKIPA Announces FDA Clearance of IND Application for HB-201 Clinical Trial to Treat HPV-Positive Cancers GlobeNewswire
02:05PM  [video]Hookipa Soars on FDA OK of Early Stage Trial For Cancer Treatment
Jun-10-19 09:10AM  CEO of Agrios Global Holdings Ltd. Presenting at The Advantage Strategy and Financial Conference June 14, 2019, in Vienna, Austria CNW Group +7.28%
May-20-19 04:01PM  HOOKIPA Pharma Reports First Quarter 2019 Financial Results and Recent Business Highlights GlobeNewswire
May-08-19 03:47AM  HOOKIPA Achieves Research Milestone in HBV Collaboration and License Agreement with Gilead GlobeNewswire
Apr-25-19 08:30AM  HOOKIPA Appoints David R. Kaufman to its Board of Directors GlobeNewswire
Apr-18-19 11:01AM  Hookipa Pharma shares off to lackluster start in trading debut MarketWatch
07:26AM  5 things to know about Hookipa Pharma ahead of its IPO MarketWatch
Apr-17-19 10:49PM  HOOKIPA Pharma Announces Pricing of Initial Public Offering GlobeNewswire
Apr-14-19 09:53AM  IPO Outlook For The Week: Pinterest, Zoom, Biotechs, Minerals And Catastrophe Insurance Benzinga
HOOKIPA Pharma Inc., a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors. Its lead oncology product candidates are HB-201 and HB-202 that are in preclinical studies for the treatment of human papillomavirus-positive cancers. The company has a collaboration with Gilead Sciences, Inc. to develop arenavirus based therapeutics to treat hepatitis B virus and human immunodeficiency virus infections. HOOKIPA Pharma Inc. was founded in 2011 and is headquartered in New York, New York.